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Introduction
Sepsis in resource-limited settings will often have dif-
ferent aetiologies to those in western settings, includ-
ing severe malaria, severe dengue, viral haemorrhagic 
fevers, mellioidosis, typhus, and leptospirosis. The Sur-
viving Sepsis Campaign (SSC) guidelines [1] are mainly 
based on evidence from studies on bacterial sepsis. These 
guidelines are widely applicable, but there are also excep-
tions. We focus here on disease-specific recommenda-
tions for the management of severe falciparum malaria 
and severe dengue. An international team with extensive 
practical experience in resource-limited intensive care 
units (ICUs) identified key questions concerning the 
SSC’s management recommendations on these diseases. 
Pertinent evidence from resource-limited settings was 
evaluated using the grading of recommendations assess-
ment, development and evaluation (GRADE) tools.
Recommendations for the management of severe malaria 
and severe dengue in resource‑limited settings
Severe falciparum malaria
Severe falciparum malaria is a multi-organ disease 
caused by Plasmodium falciparum transmitted by 
Anopheles mosquitoes. The highest transmission and 
disease burden is in sub-Saharan Africa, where severe 
malaria is largely a paediatric disease, as older children 
and adults become partly immune. In Asia and South 
America, all age groups may be affected. Independ-
ent of age, the presenting symptoms with the strong-
est prognostic significance are coma (cerebral malaria), 
metabolic (lactic) acidosis and renal dysfunction. Hypo-
tension occurs infrequently (~12% of cases). One of the 
main pathophysiologic differences of severe falciparum 
malaria compared to bacterial sepsis is microcirculatory 
impairment caused by sequestration of parasite-infected 
erythrocytes, red cell rigidity and red cell clumping. 
Management requires rapid parasitological diagnosis 
by microscopy or rapid diagnostic testing (RDT) and 
prompt initiation of parenteral artesunate [2]. The SSC 
recommends that, in patients with sepsis-induced tissue 
hypoperfusion and suspicion of hypovolemia, with either 
hypotension or hyperlactatemia, an initial fluid chal-
lenge of at least 30 ml/kg of crystalloids be administered, 
of which a portion may be albumin equivalent [1]. Both 
paediatric and adult patients with severe malaria and 
tissue hypoperfusion are volume depleted intravascu-
larly. A large trial on fluid bolus therapy in 3138 African 
children with severe infections and compensated shock, 
57% of whom had falciparum malaria, showed an overall 
40% increase in mortality with fluid bolus therapy (20 or 
40 ml/kg with either saline or 5% albumin). In the 1793 
children with severe P. falciparum malaria, mortality in 
the bolus groups was 51% higher [RR 1.51 (1.17–1.95)] 
[3]. In Asian studies of adult severe malaria, rapid fluid 
resuscitation did not improve metabolic acidosis [4, 5] 
and transpulmonary thermodilution-guided rapid fluid 
resuscitation resulted in pulmonary oedema in 8/28 
(29%) patients [5]. One observational study from Myan-
mar showed no deterioration in renal function or plasma 
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lactate with maintenance fluid therapy between 1.3 and 
2.2 ml/kg/h [6]. We recommend against the use of fluid 
bolus therapy in normotensive patients with severe fal-
ciparum malaria (1A). In normotensive patients, we 
suggest initial (24 h) crystalloid fluid therapy of 2–4 ml/
kg/h, which may subsequently be reduced to 1 ml/kg/h in 
patients receiving additional fluids, e.g. through enteral 
tube feeding (2D). We suggest fluid bolus therapy (30 ml/
kg) with an isotonic crystalloid in patients with hypoten-
sive shock and, if available, early initiation of vasopressor 
support (ungraded) (Table 1).
The SSC suggests administering enteral feeding within 
the first 48 h after diagnosing severe sepsis. In resource-
limited settings, endotracheal intubation of comatosed 
patients is often not practised. In a randomised trial in 
non-intubated predominantly adult Bangladeshi patients 
with cerebral malaria, early enteral feeding (<36 h), was 
associated with aspiration pneumonia in 9/27 (33%) as 
compared to 0/29 when feeding was commenced after 
60  h [7]. No difference in hypoglycaemia incidence was 
observed. We suggest initiating enteral feeding in non-
intubated adult patients with cerebral malaria after 60 h 
(2B). There are insufficient data on paediatric patients 
with cerebral malaria from African settings. For patients 
with sepsis-induced respiratory failure, low tidal vol-
ume (6  mL/kg) mechanical ventilation is recommended 
conform the SSC. In patients with cerebral malaria, we 
suggest against the use of permissive hypercapnia to 
achieve this goal, since this may exacerbate brain swelling 
(ungraded).
Severe dengue
Severe dengue is caused by dengue virus transmitted 
by Aedes mosquitoes. Approximately 1–5% of patients 
will develop severe manifestations. The defining feature 
is a vasculopathy with increased capillary permeability, 
causing plasma leakage, reduced intravascular volume 
and, if severe, life-threatening hypovolemic shock [8]. 
This ‘critical phase’ typically starts during the period of 
defervescense, and lasts for approximately 48  h. Bleed-
ing complications and organ involvement of the brain, 
liver, kidney and heart may be additional features, and 
occur more frequently in adult cases [9]. Diagnosis is 
commonly with combined dengue antigen (NS1) and 
antibody RDT [8]. No antiviral treatment is currently 
available (Table 1).
Unlike in bacterial sepsis, capillary leak in patients 
with severe dengue results in haemoconcentration. 
Haemorrhage, in particular from the gut, can contrib-
ute to hypovolemic shock [9]. Myocarditis is rare, but 
some depression of myocardial contractility is common. 
The World Health Organisation (WHO) guidelines on 
fluid resuscitation recommend restoration of the cir-
culation guided by pulse pressure, capillary refill time, 
haematocrit and urine output [8]. Cautious but prompt 
fluid administration is essential and should be restricted 
Table 1 Recommendations and  suggestions for  the management of  patients with  severe malaria and  severe dengue 
in resource-limited settings (with grading)
Fluid management of severe malaria We recommend not to use fluid bolus therapy in normotensive patients with severe 
falciparum malaria (1A). We suggest that patients receive maintenance isotonic crystalloid 
fluid therapy (2–4 ml/kg/h), which may subsequently be reduced to 1 ml/kg/h in patients 
receiving additional fluids, e.g. through enteral tube feeding (2D). We suggest that, in 
patients with hypotensive shock, fluid bolus therapy (30 ml/kg) with isotonic crystalloids 
be commenced (ungraded) and, if available, early initiation of vasopressor medication 
(ungraded)
Timing of enteral feeding in cerebral malaria We suggest initiating enteral feeing in non-intubated adult patients with cerebral malaria 
after 60 h, in order to limit the possibility of aspiration pneumonia (2B). There are insuf-
ficient data to make this recommendation for children with cerebral malaria
Permissive hypercapnia in ventilated cerebral malaria We suggest not to use a strategy of permissive hypercapnia to achieve ventilation with low 
tidal volumes in patients with cerebral malaria, because of the high incidence of brain 
swelling in these patients (ungraded)
Fluid management in severe dengue We recommend that fluid resuscitation in severe dengue is executed promptly and guided 
by pulse pressure, capillary refill time, haematocrit and urine output according to WHO 
guidelines, and that fluid therapy should be restricted as soon as the critical phase of the 
disease is over to avoid pulmonary oedema (1C). We recommend that rapid administra-
tion of large fluid boluses should be avoided, unless the patient is hypotensive (1D). We 
recommend that, in dengue patients with compensated shock, colloid fluids are not used 
(1A)
Use of corticosteroids in severe dengue We recommend not to use corticosteroids in the treatment of severe dengue (1B)
Use of prophylactic platelet transfusion in severe dengue We recommend not to use prophylactic platelet transfusion for thrombocytopenia in the 
absence of active bleeding complications, or other risk factors (uncontrolled arterial 
hypertension, recent stroke, head trauma or surgery, continuation of an anticoagulant 
treatment, or existing haemorrhagic diathesis) (1B)
as soon as the critical phase is over to avoid pulmo-
nary oedema [10]. We recommend fluid administration 
according to the WHO guidelines (1C). We recommend 
that rapid (<30 min) administration of large (>15 ml/kg) 
fluid boluses are avoided, unless the patient is hypoten-
sive (1D). In patients with compensated shock, colloids 
are not superior to normal saline or Ringer’s lactate for 
shock reversal, or for the prevention of recurrent shock, 
and we recommend that colloids are not used (1A) [11–
13]. There is insufficient evidence to recommend fluid 
choice in dengue hypotensive shock. The use of corticos-
teroids is not recommended (1B) [14]. Although throm-
bocytopenia is an inherent feature of severe dengue, the 
cause of bleeding is multifactorial, including a prominent 
vasculopathy. Bleeding is not prevented by platelet trans-
fusion [15]; we do not recommend platelet transfusion 
for thrombocytopenia in the absence of active bleed-
ing complications or other risk factors (1C). In cases of 
bleeding complications, we suggest transfusion of fresh-
frozen plasma (or cryoprecipitate) and platelet concen-
trate (ungraded).
Conclusions
The management of severe malaria and severe den-
gue differs in some important aspects from the treat-
ment of bacterial sepsis, in particular, regarding fluid 
management. 
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